Esperion Theraptc (ESPR)

$3.13 -0.01 (-0.32%)
Market Cap 805.76M
Revenue (ttm) 403.14M
Net Income (ttm) -22.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 68.04
Profit Margin -5.63%
Debt to Equity Ratio -0.50
Volume 8,183,879
Avg Vol 12,612,866
Day's Range N/A - N/A
Shares Out 257.43M
Stochastic %K 50%
Beta 0.91
Analysts Hold
Price Target $2.91

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
Enjoyycall
Enjoyycall Jun. 4 at 7:11 PM
$ANET $ESPR he’s a fraud. Exposed now! Not stopping
0 · Reply
Spaceequiped
Spaceequiped Jun. 4 at 6:20 PM
$ESPR Incomplete senence, use AI on your post too
0 · Reply
maxhappy
maxhappy Jun. 4 at 6:19 PM
$ESPR SHELDUNG SUCKS and always will. I wonder if I should purchase one of these for each member of management and the Board of Directors:
3 · Reply
BBRC
BBRC Jun. 4 at 6:08 PM
$ESPR it appears the board was desperate for an opinion that would justify this deal... maximizing shareholder value does not appear to be high on their priority list. Some may argue. :)
1 · Reply
BBRC
BBRC Jun. 4 at 6:03 PM
$ESPR A structural conflict that undermines the independence of their opinion.
0 · Reply
BBRC
BBRC Jun. 4 at 6:00 PM
$ESPR For those of you who asked about the location of the $36 million bonus the boys who gave the fairness opion get "only" if the deal closes. Page 79, 3rd paragraph from the bottom. Some might argue that the board never paid for a fairness opinion... what they paid was a bribe to get the opinion they wanted. Some may argue that.
0 · Reply
Gary9912
Gary9912 Jun. 4 at 4:34 PM
$ESPR Don’t be fooled, we’ve been robbed (to this point) if the deal goes through as is, we WILL get more at some point (maybe not much more, but something) through litigation. Maybe Sheldon can attract a higher bid and save his reputation 🤷‍♂️ https://consultqd.clevelandclinic.org/bempedoic-acid-appears-to-curb-vte-risk-in-statin-intolerant-patients?utm_medium=social&utm_source=twitter&utm_campaign=qd+tweets
1 · Reply
biotech_sellout
biotech_sellout Jun. 4 at 3:32 PM
$ESPR
0 · Reply
Enjoyycall
Enjoyycall Jun. 4 at 1:54 PM
$ESPR
0 · Reply
biotech_sellout
biotech_sellout Jun. 4 at 1:36 PM
$ESPR Any lawsuit updates?
0 · Reply
Latest News on ESPR
Esperion Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 6 days ago

Esperion Therapeutics Proxy statement: Proxy filing

Esperion Therapeutics Transcript: AGM 2026

May 28, 2026, 8:00 AM EDT - 7 days ago

Esperion Therapeutics Transcript: AGM 2026

Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study

2026-05-26T12:30:40.000Z - 9 days ago

Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

May 26, 2026, 8:00 AM EDT - 9 days ago

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 14, 2026, 4:30 PM EDT - 21 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

May 13, 2026, 8:00 AM EDT - 22 days ago

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 27 days ago

Esperion Therapeutics Quarterly report: Q1 2026

Esperion downgraded to Hold from Buy at Needham

2026-05-04T19:10:14.000Z - 4 weeks ago

Esperion downgraded to Hold from Buy at Needham

Esperion Therapeutics Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T19:26:03.000Z - 4 weeks ago

Esperion downgraded to Hold from Buy at Jefferies

Esperion downgraded to Neutral from Overweight at Piper Sandler

2026-05-01T18:06:50.000Z - 4 weeks ago

Esperion downgraded to Neutral from Overweight at Piper Sandler

Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T15:12:52.000Z - 4 weeks ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-05-01T12:46:24.000Z - 4 weeks ago

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 4 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 4 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Archimed to take Esperion Therapeutics private in $1.1 billion deal

May 1, 2026, 7:37 AM EDT - 4 weeks ago

Archimed to take Esperion Therapeutics private in $1.1 billion deal

Esperion to be acquired by Archimed for $3.16 per share, one CVR

2026-05-01T11:17:53.000Z - 4 weeks ago

Esperion to be acquired by Archimed for $3.16 per share, one CVR

Esperion to be Acquired by ARCHIMED

May 1, 2026, 7:00 AM EDT - 4 weeks ago

Esperion to be Acquired by ARCHIMED

Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 9:30 AM EDT - 7 weeks ago

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Esperion, Athyrium Capital enter $50M royalty financing agreement

2026-04-02T20:16:16.000Z - 2 months ago

Esperion, Athyrium Capital enter $50M royalty financing agreement

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:05 PM EDT - 2 months ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Apr 2, 2026, 4:00 PM EDT - 2 months ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion showcases new data from CLEAR Outcomes trial

2026-03-30T13:21:46.000Z - 2 months ago

Esperion showcases new data from CLEAR Outcomes trial

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

2026-03-16T10:51:45.000Z - 2 months ago

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Mar 16, 2026, 6:30 AM EDT - 2 months ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Esperion price target raised to $5 from $4 at Citizens

2026-03-13T09:36:20.000Z - 2 months ago

Esperion price target raised to $5 from $4 at Citizens

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 8:25 AM EDT - 3 months ago

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Esperion Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025

Esperion Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Annual report: Q4 2025

Esperion Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Earnings release: Q4 2025

Esperion Therapeutics Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Slides: Q4 2025

Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:52.000Z - 3 months ago

Esperion reports Q4 EPS 22c, consensus 28c

Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

2026-03-10T10:06:13.000Z - 3 months ago

Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 10, 2026, 6:00 AM EDT - 3 months ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Esperion Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Esperion Therapeutics Slides: Corporate presentation

Esperion Therapeutics Transcript: M&A announcement

Mar 3, 2026, 8:00 AM EST - 3 months ago

Esperion Therapeutics Transcript: M&A announcement

Esperion Therapeutics Press release: M&A announcement

Mar 3, 2026, 8:00 AM EST - 3 months ago

Esperion Therapeutics Press release: M&A announcement

Esperion Therapeutics Slides: M&A announcement

Mar 3, 2026, 8:00 AM EST - 3 months ago

Esperion Therapeutics Slides: M&A announcement

Esperion signs definitive acquisition of Corstasis Therapeutics

2026-03-03T11:05:38.000Z - 3 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Mar 3, 2026, 6:00 AM EST - 3 months ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 3 months ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Esperion reaches settlement agreement with Alkem

2026-02-17T13:16:28.000Z - 3 months ago

Esperion reaches settlement agreement with Alkem

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 17, 2026, 8:00 AM EST - 3 months ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 5 months ago

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Esperion Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 5 months ago

Esperion Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

2026-01-12T00:25:16.000Z - 5 months ago

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 6:00 PM EST - 5 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Esperion’s bempedoic acid receives recommendation in 2025 ACC statement

2025-12-19T13:16:23.000Z - 5 months ago

Esperion’s bempedoic acid receives recommendation in 2025 ACC statement

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 3:30 PM EST - 6 months ago

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 7:00 AM EST - 7 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:00 AM EST - 7 months ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Esperion Therapeutics Transcript: KOL Event

Nov 11, 2025, 2:00 PM EST - 7 months ago

Esperion Therapeutics Transcript: KOL Event

Esperion Therapeutics Slides: KOL Event

Nov 11, 2025, 2:00 PM EST - 7 months ago

Esperion Therapeutics Slides: KOL Event

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Esperion Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Esperion Therapeutics Quarterly report: Q3 2025

Esperion Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Esperion Therapeutics Earnings release: Q3 2025

Esperion Therapeutics Slides: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Esperion Therapeutics Slides: Q3 2025

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Nov 4, 2025, 8:00 AM EST - 7 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 8 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 8 months ago

Esperion Announces Proposed Public Offering of Common Stock

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Oct 3, 2025, 8:00 AM EDT - 8 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:00 PM EDT - 9 months ago

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:45 AM EDT - 9 months ago

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Esperion Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Quarterly report: Q2 2025

Esperion Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Earnings release: Q2 2025

Esperion Therapeutics Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Slides: Q2 2025

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 22, 2025, 8:00 AM EDT - 11 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 1 year ago

Esperion Appoints Craig Thompson to Board of Directors

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 12, 2025, 8:00 AM EDT - 1 year ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 9, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 12:30 PM EDT - 1 year ago

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 8, 2025, 6:30 AM EDT - 1 year ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

Esperion Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025

Esperion Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q1 2025

Esperion Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q1 2025

Esperion Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q1 2025

Esperion to Participate in The Citizens Life Sciences Conference

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update

Esperion Therapeutics Press release: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Press release: Status Update

Esperion Therapeutics Slides: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Status Update

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion Therapeutics Registration statement: Registration Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Registration statement: Registration Filing

Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing

Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Esperion Therapeutics Annual report: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Annual report: Q4 2024

Esperion Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q4 2024

Esperion Therapeutics Slides: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q4 2024

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Therapeutics Transcript: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event

Esperion Therapeutics Slides: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Slides: KOL Event

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Esperion Therapeutics Slides: FY 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Slides: FY 2025

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Esperion Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Quarterly report: Q3 2024

Esperion Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q3 2024

Esperion Therapeutics Slides: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q3 2024

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion to Report Third Quarter 2024 Financial Results on November 7

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Esperion Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q2 2024

Esperion Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q2 2024

Esperion Therapeutics Slides: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q2 2024

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Esperion Therapeutics Slides: Corporate Presentation

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Corporate Presentation

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jul 16, 2024, 8:00 AM EDT - 2 years ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Enjoyycall
Enjoyycall Jun. 4 at 7:11 PM
$ANET $ESPR he’s a fraud. Exposed now! Not stopping
0 · Reply
Spaceequiped
Spaceequiped Jun. 4 at 6:20 PM
$ESPR Incomplete senence, use AI on your post too
0 · Reply
maxhappy
maxhappy Jun. 4 at 6:19 PM
$ESPR SHELDUNG SUCKS and always will. I wonder if I should purchase one of these for each member of management and the Board of Directors:
3 · Reply
BBRC
BBRC Jun. 4 at 6:08 PM
$ESPR it appears the board was desperate for an opinion that would justify this deal... maximizing shareholder value does not appear to be high on their priority list. Some may argue. :)
1 · Reply
BBRC
BBRC Jun. 4 at 6:03 PM
$ESPR A structural conflict that undermines the independence of their opinion.
0 · Reply
BBRC
BBRC Jun. 4 at 6:00 PM
$ESPR For those of you who asked about the location of the $36 million bonus the boys who gave the fairness opion get "only" if the deal closes. Page 79, 3rd paragraph from the bottom. Some might argue that the board never paid for a fairness opinion... what they paid was a bribe to get the opinion they wanted. Some may argue that.
0 · Reply
Gary9912
Gary9912 Jun. 4 at 4:34 PM
$ESPR Don’t be fooled, we’ve been robbed (to this point) if the deal goes through as is, we WILL get more at some point (maybe not much more, but something) through litigation. Maybe Sheldon can attract a higher bid and save his reputation 🤷‍♂️ https://consultqd.clevelandclinic.org/bempedoic-acid-appears-to-curb-vte-risk-in-statin-intolerant-patients?utm_medium=social&utm_source=twitter&utm_campaign=qd+tweets
1 · Reply
biotech_sellout
biotech_sellout Jun. 4 at 3:32 PM
$ESPR
0 · Reply
Enjoyycall
Enjoyycall Jun. 4 at 1:54 PM
$ESPR
0 · Reply
biotech_sellout
biotech_sellout Jun. 4 at 1:36 PM
$ESPR Any lawsuit updates?
0 · Reply
Bear0927
Bear0927 Jun. 4 at 12:56 PM
$ESPR So everyone in the ANDA world is all of a sudden getting along....I sense settlement discussions are in full swing. We could have a better indication by June 16. How doesn't this change the calculus of the merger? How can you reasonably say Esperion is only worth $3.16 per share with a cheap CVR if its core drugs are protected beyond 2036? Is there a way to get an injunction against the shareholder vote pending ANDA resolution?
6 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 10:50 AM
$VKTX $PATH $APP $ESPR _)_
0 · Reply
BBRC
BBRC Jun. 3 at 8:17 PM
$ESPR Option traders think we are going to get a $0.34 to $0.44 bump. Are they correct?
4 · Reply
BBRC
BBRC Jun. 3 at 8:16 PM
$ESPR Highly abnormal trading.
0 · Reply
BBRC
BBRC Jun. 3 at 8:16 PM
$ESPR The arbitrage hedge funds are holding the cards.
1 · Reply
MrPeter
MrPeter Jun. 3 at 8:12 PM
$ESPR interesting
0 · Reply
afindling
afindling Jun. 3 at 8:02 PM
$ESPR insane volume into the close over 20% of the float has traded in 3 days this week.. huge trades to start the day and end the day.
1 · Reply
BBRC
BBRC Jun. 3 at 7:52 PM
$ESPR Do not let the facts interfere with your posts. They have great coverage. ::)
1 · Reply
NEWBIGTECH
NEWBIGTECH Jun. 3 at 7:40 PM
$ESPR
0 · Reply
BullDonald
BullDonald Jun. 3 at 6:52 PM
$ESPR that’s what JasonZemansky the real PHD was talking about. Now we all are on same page 🤣 It’s mind boggling that people still hold it. Smells like Bed Bath and beyond story.
1 · Reply
BBRC
BBRC Jun. 3 at 3:03 PM
$ESPR The Archimed boys need to get on the phone with their bankers... get that bump money ready. :)
0 · Reply
BBRC
BBRC Jun. 3 at 2:37 PM
$ESPR The stock trades approximately 3% of its float in the first hour... no price break??? 3rd high day of volume since preliminary proxy released. Will Archimed need to bump the price to get across the finish line???
0 · Reply